Skip Nav Destination
Issues
1 May 2005
-
Cover Image
Cover Image
- PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
The Biology Behind
Reviews
Human Cancer Biology
Ferritin Contributes to Melanoma Progression by Modulating Cell Growth and Sensitivity to Oxidative Stress
Alfonso Baldi; Daniela Lombardi; Patrizia Russo; Emanuele Palescandolo; Antonio De Luca; Daniele Santini; Feliciano Baldi; Luigi Rossiello; Maria Lucia Dell'Anna; Arianna Mastrofrancesco; Vittoria Maresca; Enrica Flori; Pier Giorgio Natali; Mauro Picardo; Marco G. Paggi
Imaging, Diagnosis, Prognosis
Int6 Expression Can Predict Survival in Early-Stage Non–Small Cell Lung Cancer Patients
Fiamma Buttitta; Carla Martella; Fabio Barassi; Lara Felicioni; Simona Salvatore; Sandra Rosini; Tommaso D'Antuono; Antonio Chella; Felice Mucilli; Rocco Sacco; Andrea Mezzetti; Franco Cuccurullo; Robert Callahan; Antonio Marchetti
Serum Human Telomerase Reverse Transcriptase Messenger RNA as a Novel Tumor Marker for Hepatocellular Carcinoma
Norimasa Miura; Yoshiko Maeda; Takamasa Kanbe; Hiroaki Yazama; Yohei Takeda; Reina Sato; Tomoe Tsukamoto; Emi Sato; Akira Marumoto; Tomomi Harada; Akiko Sano; Yosuke Kishimoto; Yasuaki Hirooka; Yoshikazu Murawaki; Junichi Hasegawa; Goshi Shiota
Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy
Michael J. Morris; Timothy Akhurst; Steven M. Larson; Marisa Ditullio; Elaina Chu; Karen Siedlecki; David Verbel; Glenn Heller; W. Kevin Kelly; Susan Slovin; Lawrence Schwartz; Howard I. Scher
Increased Expression of Insulin-Like Growth Factor I and/or Its Receptor in Gastrinomas Is Associated with Low Curability, Increased Growth, and Development of Metastases
Masayuki Furukawa; Mark Raffeld; Carmen Mateo; Akio Sakamoto; Terry W. Moody; Tetsuhide Ito; David J. Venzon; Jose Serrano; Robert T. Jensen
Expression of Cell Cycle–Regulated Proteins pRB2/p130, p107, E2F4, p27, and pCNA in Salivary Gland Tumors: Prognostic and Diagnostic Implications
Giuseppe Russo; Alessandra Zamparelli; Candace M. Howard; Corrado Minimo; Cristiana Bellan; Giovanna Carillo; Luigi Califano; Lorenzo Leoncini; Antonio Giordano; Pier Paolo Claudio
Prognostic Role of a Multigene Reverse Transcriptase-PCR Assay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant Systemic Therapy
Francisco J. Esteva; Aysegul A. Sahin; Massimo Cristofanilli; Kevin Coombes; Sang-Joon Lee; Joffre Baker; Maureen Cronin; Michael Walker; Drew Watson; Steven Shak; Gabriel N. Hortobagyi
YKL-40 Expression is Associated with Poorer Response to Radiation and Shorter Overall Survival in Glioblastoma
Christopher E. Pelloski; Anita Mahajan; Moshe Maor; Eric L. Chang; Shiao Woo; Mark Gilbert; Howard Colman; Helen Yang; Alicia Ledoux; Hilary Blair; Sandra Passe; Robert B. Jenkins; Kenneth D. Aldape
Cancer Therapy: Clinical
A Phase I Clinical Trial of Thoracic Radiotherapy and Concurrent Celecoxib for Patients with Unfavorable Performance Status Inoperable/Unresectable Non–Small Cell Lung Cancer
Zhongxing Liao; Ritsuko Komaki; Luka Milas; Chen Yuan; Merrill Kies; Joe Y. Chang; Melenda Jeter; Thomas Guerrero; George Blumenschien; Cheryl M. Smith; Frank Fossella; Barry Brown; James D. Cox
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
James L. Gulley; Philip M. Arlen; Anne Bastian; Steven Morin; Jennifer Marte; Patricia Beetham; Kwong-Yok Tsang; Junko Yokokawa; James W. Hodge; Cynthia Ménard; Kevin Camphausen; C. Norman Coleman; Francis Sullivan; Seth M. Steinberg; Jeffrey Schlom; William Dahut
A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer
Kathy D. Miller; Jose Manuel Trigo; Catherine Wheeler; Alan Barge; Jacqui Rowbottom; George Sledge; Jose Baselga
Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers
Ramesh K. Ramanathan; Donald L. Trump; Julie L. Eiseman; Chandra P. Belani; Sanjiv S. Agarwala; Eleanor G. Zuhowski; Jing Lan; Douglas M. Potter; S. Percy Ivy; Sakkaraiappan Ramalingam; Adam M. Brufsky; Michael K.K. Wong; Susan Tutchko; Merrill J. Egorin
Enhanced Pharmacodynamic and Antitumor Properties of a Histone Deacetylase Inhibitor Encapsulated in Liposomes or ErbB2-Targeted Immunoliposomes
Daryl C. Drummond; Corina Marx; Zexiong Guo; Gary Scott; Charles Noble; Donghui Wang; Maria Pallavicini; John W. Park; Dmitri B. Kirpotin; Christopher C. Benz
Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1
E. Ruth Plummer; Mark R. Middleton; Christopher Jones; Anna Olsen; Ian Hickson; Peter McHugh; Geoffrey P. Margison; Gail McGown; Mary Thorncroft; Amanda J. Watson; Alan V. Boddy; A. Hilary Calvert; Adrian L. Harris; David R. Newell; Nicola J. Curtin
A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer
Grace K. Dy; James P. Thomas; George Wilding; Laura Bruzek; Sumithra Mandrekar; Charles Erlichman; Dona Alberti; Kim Binger; Henry C. Pitot; Steven R. Alberts; Lorelei J. Hanson; Rebecca Marnocha; Kendra Tutsch; Scott H. Kaufmann; Alex A. Adjei
Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer
John R. Goffin; Ian C. Anderson; Jeffrey G. Supko; Joseph Paul Eder, Jr.; Geoffrey I. Shapiro; Thomas J. Lynch; Margaret Shipp; Bruce E. Johnson; Arthur T. Skarin
Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate
Jorge Cortes; Moshe Talpaz; Susan O'Brien; Dan Jones; Rajyalakshmi Luthra; Jenny Shan; Francis Giles; Stefan Faderl; Srdan Verstovsek; Guillermo Garcia-Manero; Mary B. Rios; Hagop Kantarjian
Cancer Therapy: Preclinical
Resistance to the Tubulin-Binding Agents in Renal Cell Carcinoma: No Mutations in the Class I β-Tubulin Gene but Changes in Tubulin Isotype Protein Expression
Roisean E. Ferguson; Claire Taylor; Anthea Stanley; Elizabeth Butler; Adrian Joyce; Patricia Harnden; Poulam M. Patel; Peter J. Selby; Rosamonde E. Banks
Blockade of Paracrine Supply of Insulin-Like Growth Factors Using Neutralizing Antibodies Suppresses the Liver Metastasis of Human Colorectal Cancers
Shin'ichi Miyamoto; Michio Nakamura; Kenya Shitara; Kazuyasu Nakamura; Yuji Ohki; Genichiro Ishii; Masato Goya; Keiji Kodama; Takafumi Sangai; Hiroyuki Maeda; Zhang Shi-chuang; Tsutomu Chiba; Atsushi Ochiai
Metabolic Signatures Associated with a NAD Synthesis Inhibitor–Induced Tumor Apoptosis Identified by 1H-Decoupled-31P Magnetic Resonance Spectroscopy
Manickam Muruganandham; Alan A. Alfieri; Cornelia Matei; Yuchun Chen; George Sukenick; Isabel Schemainda; Max Hasmann; Leonard B. Saltz; Jason A. Koutcher
Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity
Paul Beaudry; Jeremy Force; George N. Naumov; Andrew Wang; Cheryl H. Baker; Anderson Ryan; Shay Soker; Bruce E. Johnson; Judah Folkman; John V. Heymach
Cancer Prevention
Expression of HOXB2, a Retinoic Acid Signaling Target in Pancreatic Cancer and Pancreatic Intraepithelial Neoplasia
Davendra Segara; Andrew V. Biankin; James G. Kench; Catherine C. Langusch; Amanda C. Dawson; David A. Skalicky; David C. Gotley; Maxwell J. Coleman; Robert L. Sutherland; Susan M. Henshall
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.